Valeant Pharmaceuticals was upgraded to buy from hold by TheStreet Ratings on Tuesday. TheStreet Ratings gives Valeant Pharmaceuticals a B grade and $84.55 price target. The stock closed Thursday at $54.76 and has risen 17.28% year to date.
Google parent Alphabet has the strongest and most diversified long-term growth prospects.
Jim Cramer ponders what motivates someone to call a market top, and talks about how the market could be playing 'The Price Is Wrong.'
It's better to be early than wrong. Though being wrong isn't so awful.
Icahn may have a tough time finding interest in this behemoth.